Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Onchocerciasis Treatment Market by Treatment (Medication, Supportive Care, Surgery), by Drug (Stromectol, Ivermectin, Moxidectin), by Route of Administration (Oral, Parenteral), by End User (Hospitals, Specialty Centers, Others) and by DISTRIBUTION CHANNEL (Hospital Pharmacy, Retail Pharmacy, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A11537

Pages: NA

Charts: NA

Tables: NA

Onchocerciasis Treatment Market Statistics 2028 -

Onchocerciasis, commonly known as river blindness, is a disease caused by infection with Onchocerca volvulus, a parasitic worm. Symptoms of onchocerciasis include bumps under the skin, severe itching, and blindness. Onchocerciasis is the second most common cause of blindness due to an infection after trachoma. The disease is transmitted through the bites of infected blackflies. These blackflies breed along streams and fast-flowing rivers that are close to villages located near agricultural land. In the human body, the adult worms that cause onchocerciasis produce microfilariae (embryonic larvae) that can migrate to the eyes, skin, and other organs. People living in African countries are mostly infected by this disease.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the onchocerciasis treatment market.

Top Impacting Factors

The emergence of effective generic drugs for the treatment of onchocerciasis is one of the factors that is expected to influence the growth of the onchocerciasis treatment market during the forecast period.

Increase in focus of governments in developing nations on creating awareness for onchocerciasis and developing healthcare infrastructure are additional positive factors that are assessed to quicken the growth of the onchocerciasis treatment market.

With these factors influencing the growth of the market, the market capitalization of small players in the market is increasing with a rise in the number of strategic partnerships. Rise in competition between these companies will lead to qualitative developments in the market.

However, one of the drugs that is used for onchocerciasis treatment called ivermectin is known to have troublesome manufacturing procedures, which lead to its high value. With high value comes the confined utilization of this drug, which impedes the onchocerciasis treatment market growth.

Key Market Trends

Different key players in the market have motivated advancements in the field of onchocerciasis therapy. This includes the use of medical campaigns, quick track survey conventions, and government funding in developing nations such as Africa. With government funding, the cost of onchocerciasis treatment drugs can be cut down and the distribution could become easier.

Africa leads the global onchocerciasis market. The robust growth of the market in Africa can be attributed to rise in cases of intense and sustained exposure to blackfly bites. Moreover, there is low awareness in this region regarding onchocerciasis transmission. However, the government is taking initiatives to solve this problem and increase onchocerciasis awareness.

The substantial growth of the onchocerciasis treatment market will be witnessed in South America and Latin America, as the market in these regions is untapped with the growing number of onchocerciasis cases.

Key players in the market are focused on research and development activities for innovations in onchocerciasis therapies. In addition, many players are entering the global onchocerciasis treatment market with a prime focus on developing nations during the forecast period.

Key Benefits of the Report

  • This study presents the analytical depiction of the onchocerciasis treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the onchocerciasis treatment market share.
  • The current market is quantitatively analyzed to highlight the growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Onchocerciasis Treatment Report

  • Which are the leading players active in the onchocerciasis treatment market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the onchocerciasis treatment market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is onchocersiasis?
  • What is the onchocerciasis treatment market prediction in the future?
  • What are the current trends and predicted trends?

Key Market Segments

  • By Treatment
    • Medication
    • Supportive Care
    • Surgery
  • By Drug
    • Stromectol
    • Ivermectin
    • Moxidectin
  • By Route of Administration
    • Oral
    • Parenteral
  • By End User
    • Hospitals
    • Specialty Centers
    • Others
  • By DISTRIBUTION CHANNEL
    • Hospital Pharmacy
    • Retail Pharmacy
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA


Key Market Players

  • Mayne Pharma Group
  • Merck & Co., Inc.
  • Taj Pharmaceuticals Limited
  • Par Pharmaceutical Companies, Inc
  • Delta Pharma Ltd
  • Life Pharmaceutical Company
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ONCHOCERCIASIS TREATMENT MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Medication

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Supportive Care

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Surgery

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: ONCHOCERCIASIS TREATMENT MARKET, BY DRUG

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug

    • 5.2. Stromectol

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Ivermectin

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Moxidectin

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ONCHOCERCIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Route Of Administration

    • 6.2. Oral

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Parenteral

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: ONCHOCERCIASIS TREATMENT MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Specialty Centers

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Others

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: ONCHOCERCIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Distribution Channel

    • 8.2. Hospital Pharmacy

      • 8.2.1. Key Market Trends, Growth Factors and Opportunities

      • 8.2.2. Market Size and Forecast, By Region

      • 8.2.3. Market Share Analysis, By Country

    • 8.3. Retail Pharmacy

      • 8.3.1. Key Market Trends, Growth Factors and Opportunities

      • 8.3.2. Market Size and Forecast, By Region

      • 8.3.3. Market Share Analysis, By Country

    • 8.4. Others

      • 8.4.1. Key Market Trends, Growth Factors and Opportunities

      • 8.4.2. Market Size and Forecast, By Region

      • 8.4.3. Market Share Analysis, By Country

  • CHAPTER 9: ONCHOCERCIASIS TREATMENT MARKET, BY REGION

    • 9.1. Market Overview

      • 9.1.1 Market Size and Forecast, By Region

    • 9.2. North America

      • 9.2.1. Key Market Trends and Opportunities

      • 9.2.2. Market Size and Forecast, By Treatment

      • 9.2.3. Market Size and Forecast, By Drug

      • 9.2.4. Market Size and Forecast, By Route Of Administration

      • 9.2.5. Market Size and Forecast, By End User

      • 9.2.6. Market Size and Forecast, By Distribution Channel

      • 9.2.7. Market Size and Forecast, By Country

      • 9.2.8. U.S. Onchocerciasis Treatment Market

        • 9.2.8.1. Market Size and Forecast, By Treatment
        • 9.2.8.2. Market Size and Forecast, By Drug
        • 9.2.8.3. Market Size and Forecast, By Route Of Administration
        • 9.2.8.4. Market Size and Forecast, By End User
        • 9.2.8.5. Market Size and Forecast, By Distribution Channel
      • 9.2.9. Canada Onchocerciasis Treatment Market

        • 9.2.9.1. Market Size and Forecast, By Treatment
        • 9.2.9.2. Market Size and Forecast, By Drug
        • 9.2.9.3. Market Size and Forecast, By Route Of Administration
        • 9.2.9.4. Market Size and Forecast, By End User
        • 9.2.9.5. Market Size and Forecast, By Distribution Channel
      • 9.2.10. Mexico Onchocerciasis Treatment Market

        • 9.2.10.1. Market Size and Forecast, By Treatment
        • 9.2.10.2. Market Size and Forecast, By Drug
        • 9.2.10.3. Market Size and Forecast, By Route Of Administration
        • 9.2.10.4. Market Size and Forecast, By End User
        • 9.2.10.5. Market Size and Forecast, By Distribution Channel
    • 9.3. Europe

      • 9.3.1. Key Market Trends and Opportunities

      • 9.3.2. Market Size and Forecast, By Treatment

      • 9.3.3. Market Size and Forecast, By Drug

      • 9.3.4. Market Size and Forecast, By Route Of Administration

      • 9.3.5. Market Size and Forecast, By End User

      • 9.3.6. Market Size and Forecast, By Distribution Channel

      • 9.3.7. Market Size and Forecast, By Country

      • 9.3.8. France Onchocerciasis Treatment Market

        • 9.3.8.1. Market Size and Forecast, By Treatment
        • 9.3.8.2. Market Size and Forecast, By Drug
        • 9.3.8.3. Market Size and Forecast, By Route Of Administration
        • 9.3.8.4. Market Size and Forecast, By End User
        • 9.3.8.5. Market Size and Forecast, By Distribution Channel
      • 9.3.9. Germany Onchocerciasis Treatment Market

        • 9.3.9.1. Market Size and Forecast, By Treatment
        • 9.3.9.2. Market Size and Forecast, By Drug
        • 9.3.9.3. Market Size and Forecast, By Route Of Administration
        • 9.3.9.4. Market Size and Forecast, By End User
        • 9.3.9.5. Market Size and Forecast, By Distribution Channel
      • 9.3.10. Italy Onchocerciasis Treatment Market

        • 9.3.10.1. Market Size and Forecast, By Treatment
        • 9.3.10.2. Market Size and Forecast, By Drug
        • 9.3.10.3. Market Size and Forecast, By Route Of Administration
        • 9.3.10.4. Market Size and Forecast, By End User
        • 9.3.10.5. Market Size and Forecast, By Distribution Channel
      • 9.3.11. Spain Onchocerciasis Treatment Market

        • 9.3.11.1. Market Size and Forecast, By Treatment
        • 9.3.11.2. Market Size and Forecast, By Drug
        • 9.3.11.3. Market Size and Forecast, By Route Of Administration
        • 9.3.11.4. Market Size and Forecast, By End User
        • 9.3.11.5. Market Size and Forecast, By Distribution Channel
      • 9.3.12. UK Onchocerciasis Treatment Market

        • 9.3.12.1. Market Size and Forecast, By Treatment
        • 9.3.12.2. Market Size and Forecast, By Drug
        • 9.3.12.3. Market Size and Forecast, By Route Of Administration
        • 9.3.12.4. Market Size and Forecast, By End User
        • 9.3.12.5. Market Size and Forecast, By Distribution Channel
      • 9.3.13. Russia Onchocerciasis Treatment Market

        • 9.3.13.1. Market Size and Forecast, By Treatment
        • 9.3.13.2. Market Size and Forecast, By Drug
        • 9.3.13.3. Market Size and Forecast, By Route Of Administration
        • 9.3.13.4. Market Size and Forecast, By End User
        • 9.3.13.5. Market Size and Forecast, By Distribution Channel
      • 9.3.14. Rest Of Europe Onchocerciasis Treatment Market

        • 9.3.14.1. Market Size and Forecast, By Treatment
        • 9.3.14.2. Market Size and Forecast, By Drug
        • 9.3.14.3. Market Size and Forecast, By Route Of Administration
        • 9.3.14.4. Market Size and Forecast, By End User
        • 9.3.14.5. Market Size and Forecast, By Distribution Channel
    • 9.4. Asia-Pacific

      • 9.4.1. Key Market Trends and Opportunities

      • 9.4.2. Market Size and Forecast, By Treatment

      • 9.4.3. Market Size and Forecast, By Drug

      • 9.4.4. Market Size and Forecast, By Route Of Administration

      • 9.4.5. Market Size and Forecast, By End User

      • 9.4.6. Market Size and Forecast, By Distribution Channel

      • 9.4.7. Market Size and Forecast, By Country

      • 9.4.8. China Onchocerciasis Treatment Market

        • 9.4.8.1. Market Size and Forecast, By Treatment
        • 9.4.8.2. Market Size and Forecast, By Drug
        • 9.4.8.3. Market Size and Forecast, By Route Of Administration
        • 9.4.8.4. Market Size and Forecast, By End User
        • 9.4.8.5. Market Size and Forecast, By Distribution Channel
      • 9.4.9. Japan Onchocerciasis Treatment Market

        • 9.4.9.1. Market Size and Forecast, By Treatment
        • 9.4.9.2. Market Size and Forecast, By Drug
        • 9.4.9.3. Market Size and Forecast, By Route Of Administration
        • 9.4.9.4. Market Size and Forecast, By End User
        • 9.4.9.5. Market Size and Forecast, By Distribution Channel
      • 9.4.10. India Onchocerciasis Treatment Market

        • 9.4.10.1. Market Size and Forecast, By Treatment
        • 9.4.10.2. Market Size and Forecast, By Drug
        • 9.4.10.3. Market Size and Forecast, By Route Of Administration
        • 9.4.10.4. Market Size and Forecast, By End User
        • 9.4.10.5. Market Size and Forecast, By Distribution Channel
      • 9.4.11. South Korea Onchocerciasis Treatment Market

        • 9.4.11.1. Market Size and Forecast, By Treatment
        • 9.4.11.2. Market Size and Forecast, By Drug
        • 9.4.11.3. Market Size and Forecast, By Route Of Administration
        • 9.4.11.4. Market Size and Forecast, By End User
        • 9.4.11.5. Market Size and Forecast, By Distribution Channel
      • 9.4.12. Australia Onchocerciasis Treatment Market

        • 9.4.12.1. Market Size and Forecast, By Treatment
        • 9.4.12.2. Market Size and Forecast, By Drug
        • 9.4.12.3. Market Size and Forecast, By Route Of Administration
        • 9.4.12.4. Market Size and Forecast, By End User
        • 9.4.12.5. Market Size and Forecast, By Distribution Channel
      • 9.4.13. Thailand Onchocerciasis Treatment Market

        • 9.4.13.1. Market Size and Forecast, By Treatment
        • 9.4.13.2. Market Size and Forecast, By Drug
        • 9.4.13.3. Market Size and Forecast, By Route Of Administration
        • 9.4.13.4. Market Size and Forecast, By End User
        • 9.4.13.5. Market Size and Forecast, By Distribution Channel
      • 9.4.14. Malaysia Onchocerciasis Treatment Market

        • 9.4.14.1. Market Size and Forecast, By Treatment
        • 9.4.14.2. Market Size and Forecast, By Drug
        • 9.4.14.3. Market Size and Forecast, By Route Of Administration
        • 9.4.14.4. Market Size and Forecast, By End User
        • 9.4.14.5. Market Size and Forecast, By Distribution Channel
      • 9.4.15. Indonesia Onchocerciasis Treatment Market

        • 9.4.15.1. Market Size and Forecast, By Treatment
        • 9.4.15.2. Market Size and Forecast, By Drug
        • 9.4.15.3. Market Size and Forecast, By Route Of Administration
        • 9.4.15.4. Market Size and Forecast, By End User
        • 9.4.15.5. Market Size and Forecast, By Distribution Channel
      • 9.4.16. Rest of Asia Pacific Onchocerciasis Treatment Market

        • 9.4.16.1. Market Size and Forecast, By Treatment
        • 9.4.16.2. Market Size and Forecast, By Drug
        • 9.4.16.3. Market Size and Forecast, By Route Of Administration
        • 9.4.16.4. Market Size and Forecast, By End User
        • 9.4.16.5. Market Size and Forecast, By Distribution Channel
    • 9.5. LAMEA

      • 9.5.1. Key Market Trends and Opportunities

      • 9.5.2. Market Size and Forecast, By Treatment

      • 9.5.3. Market Size and Forecast, By Drug

      • 9.5.4. Market Size and Forecast, By Route Of Administration

      • 9.5.5. Market Size and Forecast, By End User

      • 9.5.6. Market Size and Forecast, By Distribution Channel

      • 9.5.7. Market Size and Forecast, By Country

      • 9.5.8. Brazil Onchocerciasis Treatment Market

        • 9.5.8.1. Market Size and Forecast, By Treatment
        • 9.5.8.2. Market Size and Forecast, By Drug
        • 9.5.8.3. Market Size and Forecast, By Route Of Administration
        • 9.5.8.4. Market Size and Forecast, By End User
        • 9.5.8.5. Market Size and Forecast, By Distribution Channel
      • 9.5.9. South Africa Onchocerciasis Treatment Market

        • 9.5.9.1. Market Size and Forecast, By Treatment
        • 9.5.9.2. Market Size and Forecast, By Drug
        • 9.5.9.3. Market Size and Forecast, By Route Of Administration
        • 9.5.9.4. Market Size and Forecast, By End User
        • 9.5.9.5. Market Size and Forecast, By Distribution Channel
      • 9.5.10. Saudi Arabia Onchocerciasis Treatment Market

        • 9.5.10.1. Market Size and Forecast, By Treatment
        • 9.5.10.2. Market Size and Forecast, By Drug
        • 9.5.10.3. Market Size and Forecast, By Route Of Administration
        • 9.5.10.4. Market Size and Forecast, By End User
        • 9.5.10.5. Market Size and Forecast, By Distribution Channel
      • 9.5.11. UAE Onchocerciasis Treatment Market

        • 9.5.11.1. Market Size and Forecast, By Treatment
        • 9.5.11.2. Market Size and Forecast, By Drug
        • 9.5.11.3. Market Size and Forecast, By Route Of Administration
        • 9.5.11.4. Market Size and Forecast, By End User
        • 9.5.11.5. Market Size and Forecast, By Distribution Channel
      • 9.5.12. Argentina Onchocerciasis Treatment Market

        • 9.5.12.1. Market Size and Forecast, By Treatment
        • 9.5.12.2. Market Size and Forecast, By Drug
        • 9.5.12.3. Market Size and Forecast, By Route Of Administration
        • 9.5.12.4. Market Size and Forecast, By End User
        • 9.5.12.5. Market Size and Forecast, By Distribution Channel
      • 9.5.13. Rest of LAMEA Onchocerciasis Treatment Market

        • 9.5.13.1. Market Size and Forecast, By Treatment
        • 9.5.13.2. Market Size and Forecast, By Drug
        • 9.5.13.3. Market Size and Forecast, By Route Of Administration
        • 9.5.13.4. Market Size and Forecast, By End User
        • 9.5.13.5. Market Size and Forecast, By Distribution Channel
  • CHAPTER 10: COMPETITIVE LANDSCAPE

    • 10.1. Introduction

    • 10.2. Top Winning Strategies

    • 10.3. Product Mapping Of Top 10 Player

    • 10.4. Competitive Dashboard

    • 10.5. Competitive Heatmap

    • 10.6. Top Player Positioning, 2024

  • CHAPTER 11: COMPANY PROFILES

    • 11.1. Merck And Co., Inc.

      • 11.1.1. Company Overview

      • 11.1.2. Key Executives

      • 11.1.3. Company Snapshot

      • 11.1.4. Operating Business Segments

      • 11.1.5. Product Portfolio

      • 11.1.6. Business Performance

      • 11.1.7. Key Strategic Moves and Developments

    • 11.2. Mayne Pharma Group

      • 11.2.1. Company Overview

      • 11.2.2. Key Executives

      • 11.2.3. Company Snapshot

      • 11.2.4. Operating Business Segments

      • 11.2.5. Product Portfolio

      • 11.2.6. Business Performance

      • 11.2.7. Key Strategic Moves and Developments

    • 11.3. Par Pharmaceutical Companies, Inc

      • 11.3.1. Company Overview

      • 11.3.2. Key Executives

      • 11.3.3. Company Snapshot

      • 11.3.4. Operating Business Segments

      • 11.3.5. Product Portfolio

      • 11.3.6. Business Performance

      • 11.3.7. Key Strategic Moves and Developments

    • 11.4. Delta Pharma Ltd

      • 11.4.1. Company Overview

      • 11.4.2. Key Executives

      • 11.4.3. Company Snapshot

      • 11.4.4. Operating Business Segments

      • 11.4.5. Product Portfolio

      • 11.4.6. Business Performance

      • 11.4.7. Key Strategic Moves and Developments

    • 11.5. Life Pharmaceutical Company

      • 11.5.1. Company Overview

      • 11.5.2. Key Executives

      • 11.5.3. Company Snapshot

      • 11.5.4. Operating Business Segments

      • 11.5.5. Product Portfolio

      • 11.5.6. Business Performance

      • 11.5.7. Key Strategic Moves and Developments

    • 11.6. Taj Pharmaceuticals Limited

      • 11.6.1. Company Overview

      • 11.6.2. Key Executives

      • 11.6.3. Company Snapshot

      • 11.6.4. Operating Business Segments

      • 11.6.5. Product Portfolio

      • 11.6.6. Business Performance

      • 11.6.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ONCHOCERCIASIS TREATMENT MARKET, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR MEDICATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR SUPPORTIVE CARE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR SURGERY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ONCHOCERCIASIS TREATMENT MARKET, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR STROMECTOL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR IVERMECTIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR MOXIDECTIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ONCHOCERCIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR ORAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR PARENTERAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL ONCHOCERCIASIS TREATMENT MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR SPECIALTY CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL ONCHOCERCIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR HOSPITAL PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR RETAIL PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL ONCHOCERCIASIS TREATMENT MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL ONCHOCERCIASIS TREATMENT MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. NORTH AMERICA ONCHOCERCIASIS TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. NORTH AMERICA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 27. U.S. ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 28. U.S. ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 29. U.S. ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 30. U.S. ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. U.S. ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 32. CANADA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 33. CANADA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 34. CANADA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 35. CANADA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. CANADA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 37. MEXICO ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 38. MEXICO ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 39. MEXICO ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 40. MEXICO ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. MEXICO ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 42. EUROPE ONCHOCERCIASIS TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 43. EUROPE ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 44. EUROPE ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 45. EUROPE ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 46. EUROPE ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. EUROPE ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 48. FRANCE ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 49. FRANCE ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 50. FRANCE ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 51. FRANCE ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. FRANCE ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 53. GERMANY ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 54. GERMANY ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 55. GERMANY ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 56. GERMANY ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. GERMANY ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 58. ITALY ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 59. ITALY ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 60. ITALY ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 61. ITALY ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. ITALY ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 63. SPAIN ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 64. SPAIN ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 65. SPAIN ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 66. SPAIN ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. SPAIN ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 68. UK ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 69. UK ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 70. UK ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 71. UK ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. UK ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 73. RUSSIA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 74. RUSSIA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 75. RUSSIA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 76. RUSSIA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. RUSSIA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 78. REST OF EUROPE ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 79. REST OF EUROPE ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 80. REST OF EUROPE ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 81. REST OF EUROPE ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. REST OF EUROPE ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 83. ASIA-PACIFIC ONCHOCERCIASIS TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 84. ASIA-PACIFIC ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 85. ASIA-PACIFIC ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 86. ASIA-PACIFIC ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 87. ASIA-PACIFIC ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 88. ASIA-PACIFIC ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 89. CHINA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 90. CHINA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 91. CHINA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 92. CHINA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. CHINA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 94. JAPAN ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 95. JAPAN ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 96. JAPAN ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 97. JAPAN ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. JAPAN ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 99. INDIA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 100. INDIA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 101. INDIA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 102. INDIA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 103. INDIA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 104. SOUTH KOREA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 105. SOUTH KOREA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 106. SOUTH KOREA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 107. SOUTH KOREA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 108. SOUTH KOREA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 109. AUSTRALIA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 110. AUSTRALIA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 111. AUSTRALIA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 112. AUSTRALIA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 113. AUSTRALIA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 114. THAILAND ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 115. THAILAND ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 116. THAILAND ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 117. THAILAND ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 118. THAILAND ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 119. MALAYSIA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 120. MALAYSIA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 121. MALAYSIA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 122. MALAYSIA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 123. MALAYSIA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 124. INDONESIA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 125. INDONESIA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 126. INDONESIA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 127. INDONESIA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 128. INDONESIA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 129. REST OF ASIA PACIFIC ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 130. REST OF ASIA PACIFIC ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 131. REST OF ASIA PACIFIC ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 132. REST OF ASIA PACIFIC ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 133. REST OF ASIA PACIFIC ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 134. LAMEA ONCHOCERCIASIS TREATMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 135. LAMEA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 136. LAMEA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 137. LAMEA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 138. LAMEA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 139. LAMEA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 140. BRAZIL ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 141. BRAZIL ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 142. BRAZIL ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 143. BRAZIL ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 144. BRAZIL ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 145. SOUTH AFRICA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 146. SOUTH AFRICA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 147. SOUTH AFRICA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 148. SOUTH AFRICA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 149. SOUTH AFRICA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 150. SAUDI ARABIA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 151. SAUDI ARABIA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 152. SAUDI ARABIA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 153. SAUDI ARABIA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 154. SAUDI ARABIA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 155. UAE ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 156. UAE ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 157. UAE ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 158. UAE ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 159. UAE ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 160. ARGENTINA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 161. ARGENTINA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 162. ARGENTINA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 163. ARGENTINA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 164. ARGENTINA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 165. REST OF LAMEA ONCHOCERCIASIS TREATMENT, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 166. REST OF LAMEA ONCHOCERCIASIS TREATMENT, BY DRUG, 2025-2033 ($MILLION)
  • TABLE 167. REST OF LAMEA ONCHOCERCIASIS TREATMENT, BY ROUTE OF ADMINISTRATION, 2025-2033 ($MILLION)
  • TABLE 168. REST OF LAMEA ONCHOCERCIASIS TREATMENT, BY END USER, 2025-2033 ($MILLION)
  • TABLE 169. REST OF LAMEA ONCHOCERCIASIS TREATMENT, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 170. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 171. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 172. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 173. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 174. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 175. MAYNE PHARMA GROUP: KEY EXECUTIVES
  • TABLE 176. MAYNE PHARMA GROUP: COMPANY SNAPSHOT
  • TABLE 177. MAYNE PHARMA GROUP: OPERATING SEGMENTS
  • TABLE 178. MAYNE PHARMA GROUP: PRODUCT PORTFOLIO
  • TABLE 179. MAYNE PHARMA GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 180. PAR PHARMACEUTICAL COMPANIES, INC: KEY EXECUTIVES
  • TABLE 181. PAR PHARMACEUTICAL COMPANIES, INC: COMPANY SNAPSHOT
  • TABLE 182. PAR PHARMACEUTICAL COMPANIES, INC: OPERATING SEGMENTS
  • TABLE 183. PAR PHARMACEUTICAL COMPANIES, INC: PRODUCT PORTFOLIO
  • TABLE 184. PAR PHARMACEUTICAL COMPANIES, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 185. DELTA PHARMA LTD: KEY EXECUTIVES
  • TABLE 186. DELTA PHARMA LTD: COMPANY SNAPSHOT
  • TABLE 187. DELTA PHARMA LTD: OPERATING SEGMENTS
  • TABLE 188. DELTA PHARMA LTD: PRODUCT PORTFOLIO
  • TABLE 189. DELTA PHARMA LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 190. LIFE PHARMACEUTICAL COMPANY: KEY EXECUTIVES
  • TABLE 191. LIFE PHARMACEUTICAL COMPANY: COMPANY SNAPSHOT
  • TABLE 192. LIFE PHARMACEUTICAL COMPANY: OPERATING SEGMENTS
  • TABLE 193. LIFE PHARMACEUTICAL COMPANY: PRODUCT PORTFOLIO
  • TABLE 194. LIFE PHARMACEUTICAL COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 195. TAJ PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 196. TAJ PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 197. TAJ PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
  • TABLE 198. TAJ PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 199. TAJ PHARMACEUTICALS LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCHOCERCIASIS TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ONCHOCERCIASIS TREATMENT MARKET
  • FIGURE 3. SEGMENTATION ONCHOCERCIASIS TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ONCHOCERCIASIS TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALONCHOCERCIASIS TREATMENT MARKET
  • FIGURE 11. ONCHOCERCIASIS TREATMENT MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 12. ONCHOCERCIASIS TREATMENT MARKET FOR MEDICATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ONCHOCERCIASIS TREATMENT MARKET FOR SUPPORTIVE CARE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ONCHOCERCIASIS TREATMENT MARKET FOR SURGERY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. ONCHOCERCIASIS TREATMENT MARKET SEGMENTATION, BY BY DRUG
  • FIGURE 16. ONCHOCERCIASIS TREATMENT MARKET FOR STROMECTOL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. ONCHOCERCIASIS TREATMENT MARKET FOR IVERMECTIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. ONCHOCERCIASIS TREATMENT MARKET FOR MOXIDECTIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ONCHOCERCIASIS TREATMENT MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 20. ONCHOCERCIASIS TREATMENT MARKET FOR ORAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. ONCHOCERCIASIS TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. ONCHOCERCIASIS TREATMENT MARKET SEGMENTATION, BY BY END USER
  • FIGURE 23. ONCHOCERCIASIS TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. ONCHOCERCIASIS TREATMENT MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. ONCHOCERCIASIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. ONCHOCERCIASIS TREATMENT MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 27. ONCHOCERCIASIS TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. ONCHOCERCIASIS TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. ONCHOCERCIASIS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: ONCHOCERCIASIS TREATMENT MARKET
  • FIGURE 36. TOP PLAYER POSITIONING, 2024
  • FIGURE 37. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. MAYNE PHARMA GROUP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. MAYNE PHARMA GROUP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. MAYNE PHARMA GROUP: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. PAR PHARMACEUTICAL COMPANIES, INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. PAR PHARMACEUTICAL COMPANIES, INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. PAR PHARMACEUTICAL COMPANIES, INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. DELTA PHARMA LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. DELTA PHARMA LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. DELTA PHARMA LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. LIFE PHARMACEUTICAL COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. LIFE PHARMACEUTICAL COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. LIFE PHARMACEUTICAL COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. TAJ PHARMACEUTICALS LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Onchocerciasis Treatment Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue